Principal Investigator
Lazaros Lekakis
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20200541
Clinical Trial Summary
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647